ReviveMed
Business Services · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Regus Kendall Sq 245 1st St 1805, Cambri...Website
www.revivemed.ioRevenue
<$5 MillionIndustry
About ReviveMed
Is ReviveMed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on ReviveMed recently announced quarterly report
Funding: Get notified immidiatlly once ReviveMed has new funding data
Congratulate Masked Content for being promoted to Masked Content at ReviveMed
Click to see if ReviveMed had a recent Job posting/layoffs
ReviveMed, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if ReviveMed is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if ReviveMed has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when ReviveMed launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to ReviveMed
Compare insights from companies similar to ReviveMed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
ReviveMed
Company Profile Activity
Activity Insights
ReviveMed is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
ReviveMed is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about ReviveMed.
ReviveMed Tech Stack
A closer look at the technologies used by ReviveMed
ReviveMed News & Media
ReviveMed Announces AI-driven Metabolomics Study with Bristol Myers Squibb
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--ReviveMed is proud to announce that they are pursuing an evaluation study with Bristol Myers Squibb (NYSE: BMY). This study will leverage ReviveMed’s artificial intelligence (AI) platform to better understand mechanisms of response and resistance to immunotherapies in patients with cancer. “We are very excited about this opportunity to work alongside industry leaders on the Bristol Myers Squibb team,” said Dr. Leila Pirhaji, ReviveMed’s Founder and CEO. “ReviveMed Receives Frost & Sullivan AI-Driven Next-Generation Metabolomics Technology Innovation Award
CAMBRIDGE, Mass.--(BUSINESS WIRE)--#AI--ReviveMed is proud to announce that they are the recipient of the North American AI-Driven Next-Generation Metabolomics Technology Innovation Award from Frost & Sullivan as part of that company's 2018 Best Practices Awards. Frost & Sullivan, which has been providing a wide range of business consulting and market research analysis for over 50 years, expects that AI will redefine the entire drug discovery and development process. Frost & SullivanReviveMed CEO Dr. Leila Pirhaji selected as a TED Fellow
CAMBRIDGE, Mass.--(BUSINESS WIRE)--lt;a href="https://twitter.com/hashtag/AI?src=hash" target="_blank"gt;#AIlt;/agt;--ReviveMed Inc, an AI-driven drug discovery platform, today announced that CEO Dr. Leila Pirhaji has been selected as a TED Fellow, joining a class of 20 change-makers from around the world to deliver a talk on the TED stage this April in Vancouver. Dr. Pirhaji was selected in recognition of her scientific and entrepreneurial work at the intersection of artificial intelligence and
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding ReviveMed
ReviveMed is a pioneering company in AI-enabled precision medicine, focusing on the analysis of metabolites to enhance disease prediction and treatment response. Their innovative platform utilizes over 10,000 metabolites to create digital metabolic twins, which provide insights into metabolic health and cancer treatment efficacy. Targeting oncology... Read More